COMPANY

Iterion Therapeutics

HQ: Houston, TX source · iteriontherapeutics.com ↗ · Southwest

Preclinical studies have shown tegavivint inhibits β-catenin activity without overt toxicity, and has been shown to not be affected by CTNNB1 gain-of-function mutations typically found in cancer cells.2-3, 5-10 In parallel with the tegavivint program, Iterion has ongoing R&D programs investigating and developing 2nd generation TBL1 inhibitors. From company website Source · Oct 13, 2026

Keywords: oncology advanced hepatocellular carcinoma Desmoid Tumor idiopathic pulmonary fibrosis

Location: Houston, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)1NIH grants

Timeline

Sep 13, 2023 Trial start Phase 1/Phase 2: A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma source ↗
Jul 15, 2018 Trial start I: Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05797805	A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma	Phase 1/Phase 2	Recruiting	Sep 13, 2023	2026-05 (estimated)
NCT03459469	Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059	I	Completed	Jul 15, 2018	May 1, 2022 (actual)

NIH awards 1

Annual award amounts. Total $300K.

May 4, 2018 NIH award 1R41HL142357-01 FY2018: $299,974 awarded for that fiscal year; activity R41 (STTR); PI LARSON, JEFFREY LEROY; recipient as written: ITERION THERAPEUTICS INC. , HOUSTON, TX. Chronic intrapulmonary delivery o source ↗